| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Elevation Oncology Inc. Common stock (NASDAQ: ELEV)
ELEV Technical Analysis
5
| As on 20th Jun 2025 ELEV STOCK Price closed @ 0.38 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.38 & Strong Sell for SHORT-TERM with Stoploss of 3.00 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ELEVSTOCK Price
| Open | 0.38 | Change | Price | % |
| High | 0.38 | 1 Day | 0.00 | 0.00 |
| Low | 0.38 | 1 Week | 0.00 | 0.00 |
| Close | 0.38 | 1 Month | 0.05 | 15.15 |
| Volume | 587040 | 1 Year | -0.25 | -39.68 |
| 52 Week High 5.17 | 52 Week Low 0.23 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| HCTI | 0.03 | 0.00% |
| NVDA | 143.85 | -1.12% |
| GNLN | 0.01 | 0.00% |
| PCSA | 0.32 | 33.33% |
| INTC | 21.08 | -1.91% |
| LMDX | 0.02 | 0.00% |
| LCID | 2.19 | -1.35% |
| NCNA | 0.10 | -16.67% |
| TSLA | 322.16 | 0.03% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ELEV Daily Charts |
ELEV Intraday Charts |
Whats New @ Bazaartrend |
ELEV Free Analysis |
|
|
ELEV Important Levels Intraday
| RESISTANCE | 0.38 |
| RESISTANCE | 0.38 |
| RESISTANCE | 0.38 |
| RESISTANCE | 0.38 |
| RESISTANCE | 0.38 |
| RESISTANCE | 0.38 |
| RESISTANCE | 0.38 |
| RESISTANCE | 0.38 |
ELEV Forecast June 2025
| 4th UP Forecast | 6.16 |
| 3rd UP Forecast | 4.31 |
| 2nd UP Forecast | 3.16 |
| 1st UP Forecast | 2.02 |
| 1st DOWN Forecast | -1.26 |
| 2nd DOWN Forecast | -2.4 |
| 3rd DOWN Forecast | -3.55 |
| 4th DOWN Forecast | -5.4 |
ELEV Weekly Forecast
| 4th UP Forecast | 3.46 |
| 3rd UP Forecast | 2.47 |
| 2nd UP Forecast | 1.86 |
| 1st UP Forecast | 1.25 |
| 1st DOWN Forecast | -0.49 |
| 2nd DOWN Forecast | -1.10 |
| 3rd DOWN Forecast | -1.71 |
| 4th DOWN Forecast | -2.70 |
ELEV Forecast2025
| 4th UP Forecast | 11.19 |
| 3rd UP Forecast | 7.72 |
| 2nd UP Forecast | 5.58 |
| 1st UP Forecast | 3.44 |
| 1st DOWN Forecast | -2.68 |
| 2nd DOWN Forecast | -4.82 |
| 3rd DOWN Forecast | -6.96 |
| 4th DOWN Forecast | -10.43 |
Elevation Oncology Inc. Common stock ( NASDAQ USA Symbol : ELEV )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ELEV Business Profile
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York. Address: 888 Seventh Avenue, New York, NY, United States, 10106
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service